Dhaval Patel
Executive Vice President & Chief Scientific Officer Sana Biotechnology
Dhaval Patel, MD, PhD, is Executive Vice President and Chief Scientific Officer of Sana Biotechnology. He previously served as Executive Vice President and Chief Scientific Officer at UCB and spent a decade at Novartis, leading research that supported multiple global drug registrations across immunology and inflammation. Earlier in his career, he held leadership roles at UNC Chapel Hill and Duke University. Dr. Patel has served on several biotech boards and earned his B.S., M.D., and Ph.D. from Duke University. He is board certified in internal medicine, rheumatology, and allergy & immunology.
Seminars
Wednesday 29th July 2026
Biopharma Leaders Fireside Chat: Clinical Reflections on the Past Year & Positioning In Vivo Cell & Gene Therapies in Pharma Portfolios
9:00 am
- Distilling the past year’s clinical and translational progress into portfolio-relevant proof points, sharpening investment, and resource allocation
- Prioritizing indications and modalities where in vivo approaches add differentiated value alongside existing assets, focusing pipeline sequencing
- Aligning global development routes, data portability, and CMC readiness with near-term regulatory and commercial realities, accelerating time to value
